SAGE Therapeutics Announces Merger with Supernus Pharmaceuticals

SAGE Therapeutics ( (SAGE) ) has issued an announcement.

On June 13, 2025, Sage Therapeutics entered into a Merger Agreement with Supernus Pharmaceuticals, where Supernus will acquire Sage through a tender offer of $8.50 per share in cash, plus contingent value rights worth up to $3.50 per share. This acquisition, expected to close in the third quarter of 2025, aims to strengthen Supernus’ neuropsychiatry product portfolio, particularly with ZURZUVAE, and is anticipated to be significantly accretive by 2026, with potential cost synergies of up to $200 million annually.

The most recent analyst rating on (SAGE) stock is a Hold with a $10.00 price target. To see the full list of analyst forecasts on SAGE Therapeutics stock, see the SAGE Stock Forecast page.

Spark’s Take on SAGE Stock

According to Spark, TipRanks’ AI Analyst, SAGE is a Neutral.

The overall stock score for SAGE Therapeutics is primarily influenced by significant financial challenges, including declining revenues and negative cash flows, leading to a low financial performance score. Technical analysis also points to a bearish trend. While the earnings call provided some positive developments, it was not enough to offset the broader financial concerns.

To see Spark’s full report on SAGE stock, click here.

More about SAGE Therapeutics

Sage Therapeutics is a biopharmaceutical company focused on pioneering solutions for brain health, with a mission to deliver life-changing medicines. Their primary product, ZURZUVAE, is the first FDA-approved oral treatment for postpartum depression, reflecting their commitment to addressing complex and underserved areas in medicine.

Average Trading Volume: 969,225

Technical Sentiment Signal: Strong Sell

Current Market Cap: $419.6M

See more data about SAGE stock on TipRanks’ Stock Analysis page.